Liplat (Pravastatin Sodium)

Pravastatin blocks HMG‑CoA reductase, the key enzyme in the liver that produces cholesterol. This inhibition reduces internal cholesterol synthesis, leading the liver to increase LDL‑receptor expression, which clears more low‑density lipoprotein from the bloodstream and lowers overall plasma cholesterol.

The exact dose of Liplat is determined by the prescribing clinician based on the patient’s cholesterol levels, cardiovascular risk profile, age, renal function and other individual factors. The prescriber will select an appropriate strength and dosing schedule that aligns with current clinical guidelines.

Safety data for pravastatin in pregnancy and lactation are limited, and statins are generally contraindicated during pregnancy because of potential fetal risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To place an order, submit an enquiry on the Liplat product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Liplat (pravastatin) is a hydrophilic statin with a lower potential for drug‑drug interactions compared with lipophilic agents such as atorvastatin. It may be preferred in patients taking multiple medications or those with a higher risk of metabolic interactions, while still providing effective LDL‑cholesterol reduction.

Liplat should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Liplat is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious adverse events linked to pravastatin include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney injury, and hepatotoxicity, which may present as significant elevations in liver enzymes or hepatitis. Prompt medical attention is required if symptoms such as muscle pain, weakness, dark urine, or jaundice develop.

Liplat is contraindicated in individuals with known hypersensitivity to pravastatin or any component of the formulation, active liver disease, unexplained persistent elevations of hepatic transaminases, and in patients who are pregnant or breastfeeding unless the benefits outweigh the risks.